Imeka is currently the only company to combine diffusion imaging and AI to map white matter integrity and get insights on neuroinflammation, demyelination and axonal loss. Therefore, with our non-invasive technology, we minimize risks for our pharma and biotech clients in the development of treatments for neurodegenerative diseases. Imeka’s main goal is to play an influential role in the search and development of cures for brain disease. Imeka’s diffusion imaging tools are able to measure extracellular water fraction (free-water), which is sensitive neuroinflammation. The technology pioneered by Imeka enhances white matter imaging and has applications in important brain disease areas such as Multiple Sclerosis, Alzheimer and Parkinson. This being said, we don’t think we hold all the answers, but we believe we are the best in the world at looking at white matter and brain connectivity, and that this is an important part of the equation. Imeka’s technology is only surpassed in ingenuity by its team, which includes Maxime Descoteaux, Ph.D., founder & CSO of Imeka. Maxime is an internationally renowned leader in medical imaging and diffusion MRI, acquisition, reconstruction, visualization and processing in many clinical applications. Any research and procedure involving the brain will definitely benefit from Imeka’s powerful diffusion MRI tools for brain imaging, specifically white matter imaging. Explore our expertise at www.imeka.ca